ONCOLYTICS BIOTECH INC. (ONCY) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $435.79M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $6.22M; Retained Earnings (Accumulated Deficit)USD $-448.18M.
- 2026-03-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $427.38M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $6.22M; Retained Earnings (Accumulated Deficit)USD $-438.74M.
- 2025-12-31: Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $419.47M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $6.22M; Retained Earnings (Accumulated Deficit)USD $-429.50M.
- 2025-06-30: Common Stock, Value, IssuedUSD (m); Additional Paid in CapitalUSD (m); Accumulated Other Comprehensive Income (Loss), Net of TaxUSD (m); Retained Earnings (Accumulated Deficit)USD (m).
ONCOLYTICS BIOTECH INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Accumulated Other Comprehensive Income CAD | Retained Earnings CAD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $435.79M | $6.22M | $-448.18M | $-6.17M | 3 month · $1.01M | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $427.38M | $6.22M | $-438.74M | $-5.13M | 3 month · $871.00K | 3 month · $77.00K | (m) | (m) |
| 2025-12-31 | $0.00 | $419.47M | $6.22M | $-429.50M | $-3.80M | 12 month · $3.10M | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | (m) | (m) | $3.70M | 3 month · $362.00K | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | (m) | (m) | $3.73M | 3 month · $845.00K | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $397.67M | $6.36M | $-400.74M | $3.30M | 12 month · $1.98M | (m) | 961.00K | -477.71M |
| 2023-12-31 | (m) | (m) | (m) | (m) | $19.60M | (m) | (m) | 544.00K | -446.00M |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 662.00K | -418.25M |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 388.00K | -393.42M |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 400.23K | -367.11M |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 464.10K | -344.61M |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 607.50K | -311.48M |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 373.73K | -294.45M |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 554.06K | -278.83M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |